-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: Karelli pearl monoanti is a humanized PD-1 monoclonal antibody independently developed by Hengrui Pharmaceuticals and with intellectual property rights.
September 3, Jiangsu Hengrui Pharmaceutical Co., Ltd. announced that its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd.," the injection kariliju single resistance was recently included in the State Drug Administration Drug Review Center to be priority review of varieties public list, the public notice period of 7 days.
Karelli pearl monoantibodies are humanized PD-1 monoclonal antibodies independently developed by Hengrui Pharmaceuticals and with intellectual property rights, and are innovative immunotherapy drugs with independent intellectual property rights in China, which have been approved for Hodgkin's lymphoma, advanced hepatocellular carcinoma, advanced esophageal squamous cancer and non-squamous non-small cell lung cancer since their listing in May 2019.
A phase II key clinical study (CAPTAIN study) of advanced nasopharyngeal cancer that failed chemotherapy after second-line and above chemotherapy began in August 2018, with the results to be presented orally at the upcoming ESMO Conference.
Hengrui Pharmaceuticals submitted an application to the Drug Review Center of the State Drug Administration on August 27, 2020 for the treatment of patients with advanced nasopharyngeal cancer who had previously received second-line and above chemotherapy, and was recently included in the list of approved varieties to be reviewed.
In addition, randomized, double-blind, placebo-controlled, multi-center Phase III clinical studies of the first-line treatment of local recurrence or distant metastatic nasopharyngeal cancer in Karelliju single-anti-combined cisplatin and Gissinabin have reached the end of effectiveness, and will provide more treatment options for patients with nasopharyngeal cancer in China in the future.
.
